Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967067 | 1.00 | GSK3A (0.59) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9941866 | 1.00 | GSK3A (0.59) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9967098 | 0.84 | GSK3A (0.56) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9967079 | 0.84 | GSK3A (0.56) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9967084 | 0.84 | GSK3A (0.56) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL17771534 | 0.83 | GSK3A (0.84) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL17771540 | 0.83 | GSK3A (0.84) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9941828 | 0.83 | GSK3A (0.84) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9967207 | 0.83 | GSK3A (0.53) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9941803 | 0.83 | GSK3A (0.53) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651938-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083122-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |